Showing results (61-70 of 80) with videos related to
Sort By:
Pageof 8
Annales De Cardiologie Et D'Angeiologie|December 15, 2016
Assessment of global longitudinal strain at low-dose anthracycline-based chemotherapy for the prediction of subsequent cardiotoxicityC Charbonnel, R Convers-Domart, S Rigaudeau, et al.British Journal of Cancer|July 19, 2006
A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemiaV Lévy, S Zohar, C Bardin, et al.The Hematology Journal : the Official Journal of the European Haematology Association|March 29, 2002
Functional G-CSF pathways in t(8;21) leukemic cells allow for differentiation induction and degradation of AML1-ETON Da Silva, S Meyer-Monard, M L Menot, et al.Leukemia|July 31, 2009
Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive valueA Hochhaus, M C Müller, J Radich, et al.Leukemia|July 23, 2004
A clinical and pharmacological study of arsenic trioxide in advanced multiple myeloma patientsP Rousselot, J Larghero, B Arnulf, et al.Leukemia|August 30, 2002
Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapyN Boissel, J M Cayuela, C Preudhomme, et al.Leukemia|March 31, 2012
First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemiaD Rea, G Etienne, F Nicolini, et al.Leukemia|November 30, 2012
Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapyS Mustjoki, K Auvinen, A Kreutzman, et al.Blood Cancer Journal|August 16, 2014
A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemiaJ F Seymour, D W Kim, E Rubin, et al.Pageof 8